JP2024105460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105460A5 JP2024105460A5 JP2024076310A JP2024076310A JP2024105460A5 JP 2024105460 A5 JP2024105460 A5 JP 2024105460A5 JP 2024076310 A JP2024076310 A JP 2024076310A JP 2024076310 A JP2024076310 A JP 2024076310A JP 2024105460 A5 JP2024105460 A5 JP 2024105460A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- diffraction pattern
- pharmaceutical composition
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 238000002441 X-ray diffraction Methods 0.000 claims 6
- 230000005855 radiation Effects 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 claims 3
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692914P | 2018-07-02 | 2018-07-02 | |
| US62/692,914 | 2018-07-02 | ||
| PCT/US2019/040276 WO2020010068A1 (en) | 2018-07-02 | 2019-07-02 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
| JP2020572517A JP2021530456A (ja) | 2018-07-02 | 2019-07-02 | ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572517A Division JP2021530456A (ja) | 2018-07-02 | 2019-07-02 | ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105460A JP2024105460A (ja) | 2024-08-06 |
| JP2024105460A5 true JP2024105460A5 (https=) | 2025-02-07 |
Family
ID=67441642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572517A Pending JP2021530456A (ja) | 2018-07-02 | 2019-07-02 | ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態 |
| JP2024076310A Pending JP2024105460A (ja) | 2018-07-02 | 2024-05-09 | ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572517A Pending JP2021530456A (ja) | 2018-07-02 | 2019-07-02 | ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210122740A1 (https=) |
| EP (2) | EP3818057A1 (https=) |
| JP (2) | JP2021530456A (https=) |
| KR (2) | KR102890565B1 (https=) |
| CN (1) | CN112638904A (https=) |
| AR (1) | AR115666A1 (https=) |
| AU (2) | AU2019298236A1 (https=) |
| CA (1) | CA3104860A1 (https=) |
| IL (2) | IL321116A (https=) |
| MX (3) | MX2021000107A (https=) |
| TW (1) | TW202019914A (https=) |
| WO (1) | WO2020010068A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4406594T (lt) | 2012-09-17 | 2025-12-29 | Madrigal Pharmaceuticals, Inc. | Skydliaukės hormono analogai |
| IL266054B2 (en) | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
| US12338206B2 (en) | 2019-02-21 | 2025-06-24 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as thyroid hormone receptor agonists |
| GEP20247637B (en) | 2019-05-08 | 2024-06-25 | Aligos Therapeutics Inc | Modulators of thr-b and methods of use thereof |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2021129465A1 (zh) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| US12595254B2 (en) | 2020-09-10 | 2026-04-07 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of Resmetirom, preparation method therefor, and use thereof |
| WO2022086894A1 (en) | 2020-10-19 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| KR20230142523A (ko) * | 2021-02-01 | 2023-10-11 | 마드리갈 파마슈티칼스, 인크. | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| WO2022225827A1 (en) * | 2021-04-21 | 2022-10-27 | Merck Sharp & Dohme Llc | Novel forms of cyclic dinucleotide compounds |
| JP2024544538A (ja) * | 2021-11-11 | 2024-12-03 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | ＴＨＲ－βアゴニストによる肝障害の治療 |
| WO2024263714A1 (en) | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025172958A1 (en) * | 2024-02-16 | 2025-08-21 | Metrochem Api Pvt Ltd | Solid state forms of resmetirom |
| WO2025231587A1 (zh) * | 2024-05-06 | 2025-11-13 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗无水晶型ch及其制备方法 |
| WO2026067708A1 (zh) * | 2024-09-30 | 2026-04-02 | 齐鲁制药有限公司 | 瑞司美替罗晶型及其制备方法和用途 |
| WO2026074443A1 (en) | 2024-10-01 | 2026-04-09 | Assia Chemical Industries Ltd. | Solid state forms of resmetirom |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| PL1919878T3 (pl) * | 2005-07-21 | 2011-03-31 | Hoffmann La Roche | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
| LT4406594T (lt) * | 2012-09-17 | 2025-12-29 | Madrigal Pharmaceuticals, Inc. | Skydliaukės hormono analogai |
| IL266054B2 (en) * | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
-
2019
- 2019-07-01 TW TW108123112A patent/TW202019914A/zh unknown
- 2019-07-01 AR ARP190101846A patent/AR115666A1/es unknown
- 2019-07-02 CA CA3104860A patent/CA3104860A1/en active Pending
- 2019-07-02 JP JP2020572517A patent/JP2021530456A/ja active Pending
- 2019-07-02 IL IL321116A patent/IL321116A/en unknown
- 2019-07-02 WO PCT/US2019/040276 patent/WO2020010068A1/en not_active Ceased
- 2019-07-02 KR KR1020217003360A patent/KR102890565B1/ko active Active
- 2019-07-02 EP EP19745399.6A patent/EP3818057A1/en not_active Withdrawn
- 2019-07-02 KR KR1020257038532A patent/KR20250167140A/ko active Pending
- 2019-07-02 EP EP24214548.0A patent/EP4552643A3/en active Pending
- 2019-07-02 US US17/257,070 patent/US20210122740A1/en not_active Abandoned
- 2019-07-02 CN CN201980056826.0A patent/CN112638904A/zh active Pending
- 2019-07-02 AU AU2019298236A patent/AU2019298236A1/en not_active Abandoned
- 2019-07-02 MX MX2021000107A patent/MX2021000107A/es unknown
-
2020
- 2020-12-23 IL IL279700A patent/IL279700A/en unknown
-
2021
- 2021-01-06 MX MX2024013198A patent/MX2024013198A/es unknown
- 2021-01-06 MX MX2023009701A patent/MX2023009701A/es unknown
-
2024
- 2024-05-09 JP JP2024076310A patent/JP2024105460A/ja active Pending
- 2024-11-15 US US18/949,309 patent/US20250074898A1/en active Pending
-
2025
- 2025-01-10 AU AU2025200189A patent/AU2025200189A1/en active Pending
- 2025-08-19 US US19/303,585 patent/US20250368626A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105460A5 (https=) | ||
| JP2023036708A5 (https=) | ||
| JP2023116503A5 (https=) | ||
| JP2021530456A5 (https=) | ||
| JP2023002516A5 (https=) | ||
| KR20080053369A (ko) | 1-클로로-4-(β-Ｄ-글루코피라노스-1-일)-2-(4-에티닐-벤질)-벤젠의 결정형, 이의 제조 방법 및 약제 제조를 위한이의 용도 | |
| JP2020511467A5 (https=) | ||
| JPWO2020010068A5 (https=) | ||
| IL157340A (en) | O salts - Desmethyl - and nalfaxine succinate and the pharmaceutical compositions containing them | |
| JP5184511B2 (ja) | 新しい結晶形態のラミブジン | |
| JP2024177569A5 (https=) | ||
| TW201609720A (zh) | １，３，４－噻二唑化合物及其用於治療癌症之用途 | |
| JP2023109937A5 (https=) | ||
| JP2016539136A5 (https=) | ||
| JPWO2020257573A5 (https=) | ||
| CA2824301C (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
| JP2025165933A5 (https=) | ||
| JPWO2021033729A5 (https=) | ||
| TW201217360A (en) | New crystalline forms | |
| JP2024045113A5 (https=) | ||
| JPWO2021150723A5 (https=) | ||
| JPWO2023022912A5 (https=) | ||
| CN111630045A (zh) | 喹啉衍生物的结晶 | |
| JPWO2021252309A5 (https=) | ||
| JPWO2021219881A5 (https=) |